# Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients

> **NCT05062889** · PHASE2 · SUSPENDED · sponsor: **Gruppo Oncologico del Nord-Ovest** · enrollment: 477 (estimated)

## Conditions studied

- Stage II Colon Cancer
- Stage III Colon Cancer
- HER2-positive Colon Cancer
- RAS Wild-type Colon Cancer

## Interventions

- **DRUG:** 5-Fluorouracil continuous infusion FOLFOXIRI schedule
- **DRUG:** 5-Fluorouracil bolus FOLFOX schedule
- **DRUG:** 5-Fluorouracil continuous infusion FOLFOX schedule
- **DRUG:** Oxaliplatin FOLFOX and FOLFOXIRI schedule
- **DRUG:** Oxaliplatin CAPOX schedule
- **DRUG:** L-Leucovorin
- **DRUG:** Capecitabine
- **DRUG:** Irinotecan
- **DRUG:** Trifluridine/Tipiracil
- **DRUG:** Trastuzumab
- **DRUG:** Tucatinib

## Key facts

- **NCT ID:** NCT05062889
- **Lead sponsor:** Gruppo Oncologico del Nord-Ovest
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2023-05-17
- **Primary completion:** 2027-10
- **Final completion:** 2029-12
- **Target enrollment:** 477 (ESTIMATED)
- **Why stopped:** due to earlier termination of the agreement between the Sponsor and Central Laboratory for screening test. Enrollment will reopen as soon as a new laboratory is identified.
- **Last updated:** 2026-02-03

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05062889

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05062889, "Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05062889. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*